TTA
Tetradecyl Thioacetic Acid (TTA) is a synthetic drug that activates PPAR (peroxisome proliferator-activated receptor) comparable to endogenous fatty acids. PPAR is a nuclear receptor that regulates metabolism and inflammation. TTA has been shown to have anti-inflammatory and metabolic effects, making it a potential treatment for metabolic disorders such as obesity and type 2 diabetes. TTA has also been found to improve cardiovascular function and enhance exercise performance.
A study published in the Journal of Lipid Research in 2011 found that TTA supplementation improved glucose clearance and insulin sensitivity in obese mice fed a high-fat diet. Another study published in PPAR Research in 2014 showed that TTA administration reduced body weight, improved insulin sensitivity, and decreased inflammation in obese diabetic rats. A 2018 study published in Biomedicine & Pharmacotherapy found that TTA supplementation improved exercise performance, increased endurance, and decreased lactate accumulation in male Wistar rats.
The recommended dosage of TTA varies depending on the individual and the intended use of the drug. However, typical dosages range from 50 to 300 mg per day. More research is needed to establish the optimal dosage and potential side effects of TTA.
